TRxADE HEALTH Valuation
Is 4e+40 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4e+40 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4E40 (€6.86) is trading above our estimate of fair value (€0.12)
Significantly Below Fair Value: 4E40 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4e+40?
Other financial metrics that can be useful for relative valuation.
What is 4e+40's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$9.33m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1x |
Enterprise Value/EBITDA | -4.2x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 4e+40's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 1.3x | ||
IS8 ifa systems | 0.9x | n/a | €7.7m |
IS8 ifa systems | 0.8x | n/a | €7.3m |
AJ91 DocCheck | 0.9x | n/a | €45.9m |
M3V MeVis Medical Solutions | 2.8x | n/a | €48.0m |
4E40 TRxADE HEALTH | 1x | n/a | €9.3m |
Price-To-Sales vs Peers: 4E40 is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (4.3x).
Price to Earnings Ratio vs Industry
How does 4e+40's PE Ratio compare vs other companies in the European Healthcare Services Industry?
Price-To-Sales vs Industry: 4E40 is good value based on its Price-To-Sales Ratio (1x) compared to the European Healthcare Services industry average (2.3x).
Price to Sales Ratio vs Fair Ratio
What is 4e+40's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 1x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 4E40's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.